Damora Therapeutics (DMRA) Director Andrew Cheng Receives Award

What Happened
Andrew Cheng, a director of Damora Therapeutics, was granted a derivative award on Aug 12, 2026 that covers 30,350 shares of common stock. The Form 4 reports the acquisition at $0.00 per share (total reported value $0), indicating an award/option-style grant rather than an open-market purchase or sale.

Key Details

• Transaction type/code: Award/Grant (A) of a derivative right to acquire 30,350 shares.
• Transaction date: 2026-08-12; Form 4 filed 2026-08-13 (timely filing).
• Price reported: $0.00 per share (no cash paid at grant per filing).
• Vesting: The award vests in equal monthly installments through Aug 12, 2029, subject to continued service (see footnote).
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Footnote: Confirms the award is a right to purchase common stock and details the monthly vesting schedule.

Context
This is a compensation-related derivative award (a right to purchase shares) rather than an immediate purchase or sale of stock. Such grants are common for directors and typically reflect compensation/retention terms; they do not necessarily indicate the insider’s near-term view on the company’s stock. No immediate cash or sale of shares occurred in this filing.